Description

Endo International plc is a specialty pharmaceutical company that develops, manufactures, and markets both branded and generic medications across the United States and globally. Its operations are divided into several key segments: Branded Pharmaceuticals: This division offers a portfolio of signature prescription medications, addressing conditions such as Dupuytren's contracture (XIAFLEX), central precocious puberty (SUPPRELIN LA), vitamin B12 deficiency (NASCOBAL), hypogonadism (AVEED), and moderate-to-severe cellulite (QWO). It also includes treatments for moderate to moderately severe pain (PERCOCET), testosterone replacement therapy (TESTOPEL), erectile dysfunction (EDEX), and pain relief with topical patches (LIDODERM), among other pain management and urology products. Sterile Injectables: This segment is responsible for producing essential branded formulations like VASOSTRICT (a vasopressin injection) and ADRENALIN (an adrenergic agonist), as well as APLISOL, a sterile aqueous solution. It also develops and supplies various generic sterile injectable products, including ertapenem and ephedrine sulfate injections. Generic Pharmaceuticals: This segment encompasses a wide array of generic drug formulations, spanning various delivery methods including solid oral extended and immediate-release forms, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. International Pharmaceuticals: Operating globally, this segment provides specialized pharmaceutical products across diverse therapeutic categories such as attention deficit hyperactivity disorder (ADHD), pain management, women's health, oncology, and transplantation. Endo distributes its branded and generic products through a broad network of channels, reaching specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialized distributors. The company was established in 1920 and maintains its headquarters in Dublin, Ireland. A significant recent development occurred on August 16, 2022, when Endo International plc, along with its affiliated entities, initiated bankruptcy proceedings by filing a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.